House bill to allow therapeutic cannabis patients to grow limited plants advances amid safety and oversight debate

House Bill 53 would permit qualifying therapeutic cannabis patients and designated caregivers to cultivate cannabis at a private, secured location for therapeutic use, subject to registration and limits described in the bill.

Representative Wendy Thomas, sponsor of HB 53 and a registered therapeutic cannabis patient, told the House Judiciary Committee the bill would allow patients or designated caregivers to grow up to three mature (flowering) plants, three immature (nonflowering) plants and 12 seedlings (six inches or less). She described the change as a response to patient needs for affordability, accessibility and availability of specific strains: “Growing it would be a good option,” she said, noting many patients must travel long distances to the seven ATCs in the state.

Why it matters: Supporters said home cultivation would lower costs for patients who rely on cannabis for chronic conditions and expand access for people with transportation barriers. Several medical and patient witnesses testified that certain cannabinoid/strain profiles are uniquely helpful to individuals and that some patients want the option to grow the cultivars that work for them.

Supporters, safeguards and scope - Jerry Kurnirk, M.D., chair of the Therapeutic Cannabis Medical Oversight Board, said TCMOB voted unanimously to support home cultivation and that the bill contains “robust protections” such as plant-count limits, registration of cultivation sites, and a requirement that plants be enclosed, locked and not subject to public view (testimony references lines in draft language describing “locked and enclosed” cultivation spaces). - Matt Simon of Granite Leaf Cannabis and other ATC-affiliated speakers said dispensaries could offer seedlings and classes to help patients comply with the rules; ATCs stated they support the bill and would assist patients. - Testifying patients described medical and mobility reasons for wanting home cultivation; one speaker noted specific cannabinoids and cultivars she uses, and another described horticultural expertise.

Opposition and enforcement concerns - Sue Hamala of Smart Approaches to Marijuana emphasized the program’s privacy protections and argued the state lacks mechanisms and resources to monitor home cultivation effectively. She said the bill would authorize widespread home growing and cited limited enforcement tools, potential for barter or informal sales, and the privacy shield that would make law-enforcement verification more difficult. - Pat Sullivan of the New Hampshire Association of Chiefs of Police raised similar oversight concerns, warning caregivers might be able to claim costs and improperly profit and that landlords could be exposed to federal risk if cultivation occurs on leased premises without clear landlord consent.

Key operational and statutory details discussed - Plant and possession limits described in testimony: up to 3 mature flowering plants, 3 immature plants and 12 seedlings; a cultivation-location possession limit of 8 ounces of usable cannabis and a general possession limit of 2 ounces away from the cultivation site were discussed as statutory mechanics for balancing cultivation and possession limits. - Caregiver compensation: testimony referenced statutory language allowing caregivers to be reimbursed for costs (not labor) and an added cap “not to exceed $500 per calendar year” for costs associated with caregiving/growing. - Security and notice: cultivation locations must be secured, locked and not subject to public view; written landlord permission required for rental properties. - Product testing: the bill would allow home cultivators to submit material to state labs for cannabinoid profiling and contaminant testing.

Institutional positions and status - TCMOB reported unanimous support for HB 53 in committee testimony and the ATCs expressed support; witness Matt Simon said the bill has repeatedly passed the House in prior sessions and “patients feel strongly that they should be free to cultivate as their counterparts in other New England states.”

Outstanding questions and enforcement trade-offs - Law-enforcement witnesses and SAM urged clearer oversight mechanisms, raised concerns about diversion and enforcement capacity, and questioned how officials could prove a given quantity was home-grown versus purchased off-market. - Supporters said statutory limits and registration, coupled with lab-testing options, would address safety and dosing concerns.

Bottom line: Testimony showed a clear split between patient and medical advocates seeking affordability and access and enforcement/anti-legalization groups focused on oversight and diversion; the Therapeutic Cannabis Medical Oversight Board and ATCs expressed formal support for the home‑cultivation proposal.